(Boursier.com) — Pharnext a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Board, during the last General Meeting.
Guy-Charles Fanneau de La Horie has more than 20 years of experience in the pharmaceutical and biotechnology industries. He has held several international leadership positions, including at Pherecydes Pharma, Schering-Plough, Biogen and IDM, both in Europe and the United States.
He was Chairman of the Management Board for 6 years of Pherecydes Pharma, a biotechnology company which develops treatments against resistant bacterial infections responsible for many serious infections, for which he led the IPO in 2021, and Chief Executive Officer of PathoQuest, a company developing NGS-based infectious disease diagnostic technology. Between 2006 and 2013, he was also Chief Executive Officer of Néovacs, whose IPO in 2010 he coordinated.
Before that, he spent 8 years at Biogen, where he created and managed the subsidiaries in France and Benelux. During this time, he managed a sales force in the United States, generating more than $700 million and held European-wide responsibilities in marketing, regulatory affairs and medical affairs.
Mr. Fanneau de La Horie is a graduate of the National Veterinary School of Lyon (1982), he also holds an MBA from INSEAD, obtained in 1988.
©2023 Boursier.com